What Do Long-Term Studies Show for Wegovy?
Wegovy (semaglutide) trials up to 2 years demonstrate sustained weight loss of 15-17% body weight, with 83% of participants maintaining at least 10% loss after 4 years in the SELECT trial.[1][2] HbA1c reductions persist, dropping 1-1.5% in obese patients without diabetes.[3] Cardiovascular benefits include 20% lower risk of major events (heart attack, stroke, CV death) over 39.8 months in SELECT, driven by baseline high-risk patients.[2]
How Long Have Patients Been Followed?
Most data come from STEP trials (68-104 weeks) and SELECT (up to 4 years, n=17,604).[1][2] No trials exceed 4 years yet; ongoing extensions track 5+ years. Weight regain occurs if discontinued—5-10% within a year post-STEP.[4]
What About Serious Long-Term Risks?
Gallbladder issues rise: 4% symptomatic cholelithiasis vs. 2% placebo over 2 years.[1] Pancreatitis is rare (0.1-0.2%, similar to placebo).[3] No increased thyroid C-cell tumors in humans; rodent signals prompted monitoring.[5] Bone fractures and density loss appear in some GLP-1 analyses, but Wegovy-specific data show no clear signal over 2 years.[6] Chronic kidney effects neutral or protective in SELECT subgroups.[2]
Does Weight Loss Hold Up Over Time?
Yes, with adherence: 4-year SELECT showed -9.5% sustained loss vs. +1.6% gain in placebo.[2] STEP 5 (2 years): -15.2% vs. -2.6% lifestyle alone.[1] Real-world retention drops efficacy; 50% discontinue within 1 year.[7]
What Do Patients Report Long-Term?
Muscle loss averages 30-40% of total weight lost, prompting protein/exercise advice.[8] GI tolerance improves after 6-12 months; initial nausea affects 40-50%.[3] No broad cognitive or fertility signals; pregnancy registry ongoing.[5]
When Will We See 10-Year Data?
Extensions from STEP/SELECT aim for 5-7 years by 2027-2028. FDA requires 15-year CV safety post-approval, but results pending.[9]
Sources
[1]: NEJM - STEP 5 Trial
[2]: NEJM - SELECT Trial
[3]: FDA Wegovy Label
[4]: Diabetes Care - STEP Weight Regain
[5]: Novo Nordisk Safety Update
[6]: JAMA - GLP-1 Bone Effects Meta
[7]: JAMA - Real-World Retention
[8]: Obesity - Body Comp STEP
[9]: FDA Postmarketing Requirements